Alkermes plc
$34.23
▼
-0.6%
2026-04-21 05:13:01
www.alkermes.com
NMS: ALKS
Explore Alkermes plc stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$5.73 B
Current Price
$34.23
52W High / Low
$36.48 / $25.16
Stock P/E
23.69
Book Value
$10.99
Dividend Yield
—
ROCE
13.07%
ROE
14.72%
Face Value
—
EPS
$1.43
Exp Qtr EPS
—
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
2,050
Beta
0.39
Debt / Equity
3.85
Current Ratio
3.55
Quick Ratio
3.19
Forward P/E
16.73
Price / Sales
3.77
Enterprise Value
$5.04 B
EV / EBITDA
17.93
EV / Revenue
3.42
Rating
Strong Buy
Target Price
$44.24
EPS Forecast (FY)
—
Pros
- Efficient use of capital employed.
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Strong operating margin profile.
- Net margin remains healthy.
Cons
- Some data points may be missing or delayed because the source is not an official exchange feed.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Sonoma Pharmaceuticals, Inc. | $2.65 | — | $4.59 M | — | -38.66% | -81.18% | $6.92 / $2 | $1.98 |
| 2. | Perrigo Company plc | $12.04 | — | $1.66 B | 9.63% | 4.16% | -38.66% | $28.43 / $9.22 | $21.33 |
| 3. | Hims & Hers Health, Inc. | $28.91 | 56.32 | $6.55 B | — | 6.03% | 25.23% | $70.43 / $13.74 | $2.38 |
| 4. | SCYNEXIS, Inc. | $1.07 | — | $47.85 M | — | -30.16% | -16.48% | $1.31 / $0.56 | $1.13 |
| 5. | SIGA Technologies, Inc. | $4.57 | 14.06 | $327.41 M | 0% | 11.76% | 11.23% | $9.62 / $4.29 | $2.78 |
| 6. | InterCure Ltd. | $0.75 | — | $125.93 M | — | -8.41% | -16.68% | $605 / $225.3 | $7.59 |
| 7. | Regencell Bioscience Holdings Limited | $29.09 | — | $13.89 B | — | -57.45% | -54.81% | $83.6 / $0.7 | $0.01 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | |
|---|---|---|---|---|---|
| Sales | 384.55 M | 394.19 M | 390.66 M | 306.51 M | 429.99 M |
| Operating Profit | 58.1 M | 89.08 M | 92.98 M | 13.79 M | 162.69 M |
| Net Profit | 49.34 M | 82.76 M | 87.1 M | 22.46 M | 146.5 M |
| EPS in Rs | 0.3 | 0.5 | 0.52 | 0.14 | 0.88 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 1.48 B | 1.56 B | 1.66 B | 1.11 B |
| Operating Profit | 253.96 M | 420.64 M | 414.12 M | -6.09 M |
| Net Profit | 241.66 M | 367.07 M | 355.76 M | -158.27 M |
| EPS in Rs | 1.45 | 2.21 | 2.14 | -0.95 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 2.49 B | 2.06 B | 2.14 B | 1.96 B |
| Total Liabilities | 667.7 M | 590.59 M | 933.54 M | 920.23 M |
| Equity | 1.82 B | 1.46 B | 1.2 B | 1.04 B |
| Current Assets | 1.93 B | 1.42 B | 1.49 B | 1.13 B |
| Current Liabilities | 543.44 M | 465.2 M | 520.22 M | 497.74 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | 520.75 M | 439.12 M | 401.35 M | 21.04 M |
| Investing CF | 295.5 M | -111.31 M | 53.36 M | -64.54 M |
| Financing CF | 12.38 M | -494.14 M | -289.71 M | -1.57 M |
| Free CF | 480.33 M | 405.64 M | 353.31 M | -17.21 M |
| Capex | -40.42 M | -33.48 M | -48.05 M | -38.26 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | -6.36% | 49.61% | — | — |
| Earnings Growth % | 3.18% | 324.78% | — | — |
| Profit Margin % | 23.57% | 21.39% | -14.24% | — |
| Operating Margin % | 27% | 24.9% | -0.55% | — |
| Gross Margin % | 84.25% | 84.79% | 80.39% | — |
| EBITDA Margin % | 31.77% | 31.23% | 5.38% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.